Recently, a retrospective study involving 904 patients with DM and moderate-severe COVID-19 showed that the use of DPP4 inhibitors did not significantly affect mortality and clinical outcomes (Chen et al., 2020). This evidence concerns the gene DPP4 and diabetes mellitus.